Abstract: Technologies for assessing, quantifying and isolating sperm cell populations and/or subpopulations having specific genetic signatures are provided, as well as methods and systems to assess the efficacy of chromosomal differentiation processes. Compositions for identification and differentiation of X-chromosomes and Y-chromosomes in DNA are also provided.

Abstract: The present invention relates to the allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determined its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9?/?) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer's patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy.

Abstract: A method of determining the risk of metastasis of breast or lung cancer in a human subject who has or had breast or lung cancer is disclosed herein. The method is based on detecting in a sample from the subject the number of copies per cell of genes and/or genomic regions of a metastatic gene signature set disclosed herein, and determining alternations in the number of copies per cell of the genes and/or genomic regions in the signature set, as compared to the number of copies per cell in non-cancer cells, thereby determining the risk of breast/lung cancer metastasis.

Abstract: The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.

Abstract: An information processing system facilitates the extraction of a product relating to a patent or to facilitate the extraction of a patent relating to a product. An information processing system includes a database in which a term associated with a raw material recited in a claim of a patent document and a raw material that corresponds to the term are associated with each other, an acquiring unit configured to acquire patent information, and an extracting unit configured to extract a product containing a raw material that corresponds to a term recited in a claim that is identified by the patent information, with reference to the database and a correspondence between a product and a raw material contained in the product, based on whether the raw material that corresponds to the term and the raw material contained in the product match.

Abstract: Thermal control devices adapted to provide improved control and efficiency in temperature cycling are provided herein. Such thermal control device can include a thermoelectric cooler controlled in coordination with another thermal manipulation device to control an opposing face of the thermoelectric cooler and/or a microenvironment. Some such thermal control devices include a first and second thermoelectric cooler separated by a thermal capacitor. The thermal control devices can be configured in a planar configuration with a means for thermally coupling with a planar reaction vessel of a sample analyzer for use in thermal cycling in a polymerase chain reaction of the fluid sample in the reaction vessel. Methods of thermal cycling using such a thermal control devices are also provided.

Abstract: An example self-priming microfluidic structure can include a microfluidic channel including a floor and a ceiling. A channel height is defined as a distance between the floor and the ceiling. A channel height step can be in the floor, or ceiling, or both. The channel height downstream of the channel height step can be greater than the channel height upstream of the channel height step. An interior pillar can be positioned in the microfluidic channel extending from the floor to the ceiling. The interior pillar can include a widening portion at an upstream end of the interior pillar and a tapering portion at a downstream end of the interior pillar. The interior pillar can overlap the channel height step so that the interior pillar is partially upstream of the channel height step and partially downstream of the channel height step.

Abstract: The present subject matter provides, inter alia, compositions, systems, kits, and methods for diagnosing and treating small vessel diseases (SVDs).

Abstract: The method of the present invention enables efficient detection of a plurality of target nucleic acid sequences in one detection channel, by obtaining a data set of cycle/signal-change value.

Abstract: The invention provides methods and compositions for distinguishing breast cancer.

Abstract: Device for use in a biosensor comprising a multisite array of test sites, the device being useful for modulating the binding interactions between a (biomolecular) probe or detection agent and an analyte of interest from a biological by modulating the pH or ionic gradient near the electrodes in such biosensor. The device provides a biosensor which is more accurate, reliable and the results of which are more reproducible. Analytic methods for more accurately measuring an analyte of interest in a biological sample are also provided.

Abstract: System and method for identifying enumerating cross-body degradations, the system comprising a computing device designed and configured to receive a biological extraction pertaining to a user, generate a first body degradation function, wherein generating the first body degradation function further includes mapping at least a biological extraction datum of the user to a current level of physiological integrity, determining an instantaneous rate of change of the current level of physiological integrity, and generating, as a function of the current level of physiological integrity and the instantaneous rate of change of the current level of physiological integrity, a first body degradation function, determine a second body degradation function, wherein the second body degradation function describes a rate of biological degradation that is statistically associated with the first body degradation function, and generate a body degradation packet as a function of the first body degradation function and the second b

Abstract: A system, apparatus configured to dynamically vary an extraction distance between an extraction volume and a sample surface through a probe assembly height adjustment apparatus operably coupled to a motor in which a processor can move the probe assembly height adjustment apparatus to maintain the extraction distance, or tune the extraction distance to optimize sampling performance. Methods for calibrating, tuning an extraction distance between an extraction volume and a sample surface.

Abstract: High throughput personal genomic testing has created a need for robust quality control mechanisms to track sample identity, reagent integrity, and other factors with significant influence on assay performance. A method of massively parallel sequencing using an accompanying barcoded molecular standard enables one to track nucleic acid analytes to identify them by project, lot, batch, or patient. The molecular standard contains sequences present in the analyte, allowing it to be processed simultaneously without any other additional reagents. Within the molecular standard, a calibrator sequence permits assessment of fidelity of sequence determination. Additional sequences in the molecular standard may be used to manipulate the molecular standard separate from the analyte. The molecular standard can be used to benchmark sequencing platforms and assess error rates.

Abstract: An application of a RyR2 protein or a recombinant RyR2 protein in preparing an anti-heart failure medicament is provided. The recombinant RyR2 protein is a naturally occurring RyR2 protein fragment or a mutant, such as a SPRY1 domain protein, a P1 domain protein, a SPRY2 domain protein, a SPRY3 domain protein, a Handle domain protein, an HD1 domain protein, an HD2 domain protein, a central domain protein, an EF-hand domain protein, a U-motif protein, a P2 domain protein, a P2 domain fragment protein-1, a P2 domain fragment protein-2 derived from a natural RyR2 protein or a P2 mutant derived from the natural RyR2 protein. The exogenous recombinant RyR2 protein is highly expressed in both normal small animal and diseased small animal models, so that the left ventricular ejection fraction of experimental animals is improved varying degrees compared with that of a control group.

Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.

Abstract: The present invention relates to the field of microfluidics and in particular to analysing the gene expression of a cell in response to a ligand expressed in the same microfluidic compartment. By barcoding the transcriptome of the cell and of the expression system generating the ligand, the effect of the ligand on the cell expression can be discerned. The invention provides microfluidic compartments and methods for this purpose.

Abstract: Provided herein are methods of enhancing spatial resolution of an analyte using sandwich maker system. The methods and systems used herein include a first substrate that includes a plurality of probes that include a capture domain and a spatial domain and a second substrate that includes a plurality of probes comprising a capture domain and a spatial domain.

Abstract: A system writes input data to a storage device as machine-written polynucleotides; and reads machine written polynucleotides from the storage device as output data. The storage device includes a flow cell including a plurality of storage wells in which machine written polynucleotides may be stored. The storage device may include a set of electrodes corresponding to the storage wells that allow for selective interactions with wells across the surface of a flow cell. Operation of the storage device may include receiving a read request associated with a particular location in the storage device, creating a copy of a nucleotide sequence located at the particular location in the storage device, transferring the copy of the nucleotide sequence to a read location, and reading the copy of the nucleotide sequence at the read location.

Abstract: The invention relates to a method for identifying and quantifying a polypeptide from a library of polypeptides. The method comprises the steps of: 1—providing a polypeptide library and a detection tag library, 2—generating a nested library comprising the polypeptides and the detection tags, 3—sequencing the nested library, 4—selecting a member of the nested library in one or several selection steps that are independent of a physical genotype-phenotype linkage, 5—isolating the detection tag from the selected polypeptide, 6—identifying and quantifying the detection tag by mass spectrometry, 7—obtaining the sequence of the selected polypeptide. The invention also relates to a collection of polypeptides, a collection of detection tags, and a collection of plasmid vectors.

Abstract: The invention provides an apparatus including a reactionware and an analytical device for analysing a reaction, the analytical device including at least a plurality of reaction sensors and the analytical device is configured for placement of a plurality of sensors in the reaction space of the reactionware, and optionally the reaction headspace of the reactionware, and the reactionware is a reaction flask having one or more necks, and the analytical device is held in a neck of the reaction flask.

Abstract: Apparatuses and methods are provided to predict or diagnose an ischemic event, such as a stroke or a transient ischemic attack (TIA). A machine-learning model such as a neural network is generated that allows for recognition of an ECG consistent with an ischemic event. A system is trained and used to process a recording of ECG data from a patient to generate a prediction indicating a likelihood that the patient will experience a stroke. In other examples, a system is trained and used to process a recording of ECG data from a patient and detect an ischemic event for the patient who did not appear to have such an ischemic event.

Abstract: A microfluidic device is provided. The microfluidic device is used for an in vitro selective capture of biological entities suspended in a medium based on an immunoaffinity technique. The microfluidic device includes symmetric hydrofoil pillars arranged inside ellipse segments acting as a microfluidic channel, wherein the microfluidic channel provides a continuous change of attack angles between the symmetric hydrofoil pillars and the biological entities.

Abstract: Provided herein are methods of enhancing spatial resolution of an analyte using sandwich maker system. The methods and systems used herein include a first substrate that includes a plurality of probes that include poly-thymine sequence and a second substrate that includes a plurality of probes comprising a capture domain and a spatial domain.

Abstract: This disclosure provides data showing that LEFTY inhibits differentiation-promoting pathways such as BMP7/pSMAD5 in breast cancer cell lines, over and above its known role of inhibiting Nodal/pSMAD2. LEFTY competes with BMP7 to bind to its cell surface receptor BMPR2, leading to inhibition of pSMAD5. The LEFTY-BMPR2 interaction is dominant over BMP-BMPR2 in tumorigenic cells, resulting in diminished pSMAD status, whereas in non-tumorigenic cells, there is minimal LEFTY-BMPR2 interaction, increased BMP7-BMPR2 association, and elevated pSMAD. Compositions and methods for inducing or inhibiting expression and/or the activity of LEFTY and BMP proteins are described, which can be used in diagnosis and therapy of cancer and other conditions, and to promote proliferation of stem cells.

Abstract: The present disclosure provides methods and systems for various uses of cell-free nucleic acid (cfNA). Functional typing of cfNA fragmentation patterns may be utilized in the non-invasive detection, diagnosis, and monitoring of disease. One embodiment may determine a stage of cancer in a subject, the progression of cancer in a subject, or the responsiveness to treatment of a cancer in a subject. Another embodiment disclosed herein may include sequencing-free diagnostic methods.

Abstract: The present invention is directed to the method for selecting an RNA molecule that binds to a target molecule and a kit for carrying out the method. This method includes: providing a pool of oligonucleotide complexes that each comprise a ds-DNA molecule and an RNA molecule, the ds-DNA molecule comprising a first DNA strand at least partially annealed to a first region of the RNA molecule, whereby a second region of the RNA molecule is free to adopt a secondary structure; exposing the pool to a target molecule and allowing the second region of the RNA to bind the target molecule; and selecting from the pool one or more oligonucleotide complexes comprising an RNA molecule having the second region bound to the target molecule.

Abstract: The present disclosure provides methods, compositions, kits, and systems useful in the determination and evaluation of the immune repertoire. In one aspect, target-specific primer panels provide for the effective amplification of sequences of T cell receptor and/or B cell receptor chains with improved sequencing accuracy and resolution over the repertoire. Variable regions associated with the immune cell receptor are resolved to effectively portray clonal diversity of a biological sample and/or differences associated with the immune cell repertoire of a biological sample.

Abstract: Disclosed herein include systems, methods, compositions, and kits for associating single cell sequencing data with phenotypic data and/or agent exposure. In some embodiments, cell indexing oligonucleotides comprising cell indexing sequences are associated with cells. In some embodiments, synthetic particles are associated with stochastic labels comprising cell indexing sequences. Sequential hybridizing and imaging of probes annealing to a cell indexing sequence can generate a spatial index. The spatial index can be employed to identify of the partition from which a sequenced nucleic acid target molecule originated.

Abstract: The invention comprises a method of amplifying nucleic acids by primer extension with reduced formation of primer-primer byproducts.

Abstract: Present disclosure provides a method including isolating DNA from a source, thereby providing a composition including the isolated DNA. The isolated DNA has at least first and second target regions, where the length of the second target region is greater than the length of the first target region. The method further includes quantifying a total mass of the isolated DNA, quantifying a first quantification cycle (Cq) of the first target region and a second Cq of the second target region, and calculating a Q-ratio for the isolated DNA by dividing the second Cq by the first Cq. The method further includes determining a value for a quality-mass constant (kQm), estimating a required input mass by dividing kQm by the Q-ratio, and preparing the isolated DNA for sequencing if the total mass of the isolated DNA in the composition is equal or greater than the required input mass.

Abstract: Contemplated systems and methods use identification and classification of somatic single nucleotide variants found in a primary tumor and metastases to determine phylogeny of the metastases.

Abstract: Provided herein are methods for capturing a connected probe and/or a capture handle sequence to a capture domain of a capture probe.

Abstract: Arrays of single molecules and methods of producing an array of single molecules are described. Arrays with defined volumes between 10 attoliters and 50 picoliters enable single molecule detection and quantitation.

Abstract: System, including methods, apparatus, compositions, and kits, for making and using a stabilized emulsion. A method of generating a stabilized emulsion is provided. In the method, an aqueous phase may be provided. The aqueous phase may include an effective concentration of one or more skin-forming proteins. An emulsion may be formed. The emulsion may include droplets of a dispersed phase disposed in a continuous phase, with the aqueous phase being the continuous phase or the dispersed phase. The emulsion may be heated to create an interfacial skin between each droplet and the continuous phase, to transform the droplets into capsules.

Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.

Abstract: A method of predicting cancer recurrence risk for an individual includes receiving patient spatial multi-parameter cellular and sub-cellular imaging data for a tumor of the individual, and analyzing the patient spatial multi-parameter cellular and sub-cellular imaging data using a prognostic model for predicting cancer recurrence risk to determine a predicted cancer recurrence risk for the individual, wherein the joint prognostic model is based on spatial correlation statistics among features derived for a plurality of intra-tumor spatial domains from spatial multi-parameter cellular and sub-cellular imaging data obtained from a plurality of cancer patients.

Abstract: Compositions, methods and systems are provided for isolating nucleic acids. A polymerase-nucleic acid complex can be formed by mixing a polymerase enzyme comprising strand displacement activity and a mixture of double stranded nucleic acids. Nucleic acid synthesis can then be initiated by the polymerase enzyme to produce a nascent strand complementary to the first strand, thereby displacing a portion of the second strand. After halting or reducing the rate of nucleic acid synthesis, a hybridizing a hook oligonucleotide can be used hybridize to the nucleic acid through a capture region on the hook oligonucleotide that is complementary to the displaced portion of the second strand. The nucleic acid can then be isolated from the mixture of nucleic acids using the hook oligonucleotide.

Abstract: Methods of profiling the nucleic acid composition of single cells and tools for same. The methods can include isolating a single cell in a liquid droplet, lysing the single cell in the liquid droplet to release template nucleic acid from the cell, amplifying the template nucleic acid in the liquid droplet to generate amplified nucleic acid, and detecting the amplified nucleic acid in the liquid droplet. The methods can be useful for profiling expression patterns and/or detecting genetic characteristics such as single nucleotide polymorphisms. The tools include nucleic acid logic gates, including polymerase-dependent logic gates. The logic gates can perform logical operations such as YES, NOT, AND, OR, AND-NOT, NOT-AND, NOT-OR, EXCLUSIVE-OR, EXCLUSIVE-NOR, and IMPLY. The tools also include microfluidic systems for performing the methods.

Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.

Abstract: The present technology is directed to the nanoparticles for use as molecular environmental sensors. The nanoparticles comprise a photoluminescence core and a plurality of ligands bound to the core and forming a quencher permeable ligand shell. The ligands comprise a reactive or charged moiety capable of being modulated between a first stand and a second state, and the proportion of ligands in each state determine the permeability of the ligand shell to a photoluminescence quencher.

Abstract: The present invention provides an improved method of quantitative and/or qualitative analysis of a target molecule using nitrocellulose membrane (NCM). In particular, the present invention provides a porous nitrocellulose membrane that includes a surface and an organic nanostructured molecule that is non-covalently attached to the surface of NCM. The organic nanostructured molecule has a branched region that includes a plurality of terminal region (e.g., terminal end) moieties that are non-covalently attached or bound to a surface of the porous NCM. The organic nanostructured molecule also comprises a linear region that includes a covalently attached capture molecule that is adapted to selectively bind to a target molecule. The NCM of the invention provides an improved reproducibility, reliability, and selectivity compared an NCM in the absence of the organic nanostructured molecule.

Abstract: Compositions and methods for displaying antibodies in the periplasmic space of yeast cells are disclosed. In particular, antibodies are linked to a cell membrane-spanning transmembrane domain, a cell-membrane associated protein domain that is on the external face of the yeast cell membrane, a protein that binds to the inner face of the yeast cell wall, or a periplasmic protein in order to display the antibodies in the yeast periplasmic space. In addition, a target protein of interest can be coexpressed in yeast such that it is localized to the plasma membrane or periplasmic space and accessible to binding by displayed antibodies. The disclosure further relates to high-throughput screening of antibody libraries using yeast cell periplasmic display.

Abstract: An example of a flow cell includes a substrate, a plurality of chambers defined on or in the substrate, and a plurality of depressions defined in the substrate and within a perimeter of each of the plurality of chambers. The depressions are separated by interstitial regions. Primers are attached within each of the plurality of depressions, and a capture site is located within each of the plurality of chambers.

Abstract: Provided herein is a method of detecting or predicting a relapse of multiple sclerosis in an individual afflicted with a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not afflicted with the form of multiple sclerosis and patients' own baseline values. Also provided herein is a method of treating an individual afflicted with multiple sclerosis, who is experiencing a relapse or predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or anti-coagulation compound effective to alleviate the symptom of multiple sclerosis.

Abstract: Protein biomarkers may be used to rapidly and accurately diagnose stroke. Biomarkers may be utilized in a rapid and inexpensive test that could be used at the bedside or ambulatory setting to definitively indicate the presence or absence of stroke and its severity. Such a test would quickly stratify patients in need of immediate stroke treatment from those who are not having a stroke. The test may aid emergency personnel in the decision for the most appropriate treatment plan and treatment location, thereby minimizing morbidity and mortality of stroke patients.

Abstract: A peptide aptamer for specific recognition of arginine and its application are provided. The sequence of the peptide aptamer is shown in SEQ ID No. 1. The peptide aptamer is modified by a group that improves stability, or by a fluorescent group, an isotope and an electrochemical group that provide a detection signal, or by an affinity ligand and a mercapto. According to the computer-aided molecular docking simulation prediction, the peptide aptamer that can specifically bind to L-arginine is screened, which is verified by an isothermal titration calorimeter. The peptide aptamer has the advantages of good stability, strong binding ability, high specificity and low production cost.

Abstract: Provided herein are methods, assays and devices for the detection and diagnosis of autoimmune diseases, including systemic lupus erythematosus. The methods, assays and devices provided herein analyzes binding patterns of peripheral-blood antibodies on peptide array that correlates well with current systemic lupus erythematosus clinical assessment standards.

Abstract: Provided herein are methods for detecting an antigen or for detecting expression of a chimeric antigen receptor (CAR). The methods include obtaining a sample from a subject, contacting the sample with a fusion protein comprising a reporter fused to a single chain antibody specific to the antigen or fused to an extracellular domain of an antigen targeted by the CAR or fused to Protein L and assaying the activity of the reporter, wherein presence of reporter activity or increase in reporter activity relative to a reference value is indicative of presence of the antigen or presence of the expression of the chimeric antigen receptor in the sample.

Abstract: The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.